<DOC>
	<DOCNO>NCT02364024</DOCNO>
	<brief_summary>The purpose study confirm linear quantification CD3+ cell prognostic biomarker localize colorectal carcinoma .</brief_summary>
	<brief_title>Validation Study Linear Quantification CD3+ Cells Localized Colorectal Carcinomas</brief_title>
	<detailed_description>Adult patient gender underwent surgical resection stage III colorectal carcinoma randomise receive chemotherapy FOLFOX FOLFOX + Cetuximab PETACC8 trial .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patient include PETACC08 study Signed informed consent translational study FFPE tumor sample available CD3 stain Patient withdrawn consent PETACC08 and/or PETACC08 translational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Colon rectum carcinoma</keyword>
	<keyword>Immune response</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Prognosis</keyword>
</DOC>